<DOC>
	<DOCNO>NCT00246935</DOCNO>
	<brief_summary>The aim long-term study investigate effect roflumilast ( APTA-2217 ) long-term safety patient chronic obstructive pulmonary disease ( COPD ) complete 24-week evaluation study APTA-2217-06 . Roflumilast administer orally daily . The present study consist 28 week treatment period , extension 24-week study APTA-2217-06 ( register study ) . The study provide long-term safety efficacy data roflumilast .</brief_summary>
	<brief_title>Long-term Study Safety Efficacy Roflumilast Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease ( APTA-2217-08 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main inclusion criterion : Patients chronic obstructive pulmonary disease ( COPD ) Written informed consent Patients complete 24week evaluation study APTA221706 Main exclusion criterion : If patient require hospitalization receive emergency care COPD exacerbation investigator ( subinvestigator ) inform consent day start day Patients longterm oxygen therapy Serious disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Phosphodiesterase 4 inhibitor</keyword>
	<keyword>Roflumilast</keyword>
</DOC>